UCB has presented the first pooled data analysis from phase 3 trials of its bimekizumab treatment for moderate to severe hidradenitis suppurativa at the European Academy of Dermatology and Venereology (EADV) Congress. The analysis showed the treatment led to clinically important improvements and a large percentage of patients who achieved a high skin response after 16 weeks maintained their response up to 48 weeks.
AI Chatbot DeepSeek R1 Can Be Manipulated to Create Malware
Tenable Research has revealed that open-source AI chatbot DeepSeek R1 can be manipulated to generate keyloggers and ransomware. Initially refusing to write malicious code, researchers
